Randomized Clinical Trial (RCT) on the Effect of Vitamin D Supplement Prior to Non-surgical Periodontal Therapy: a Feasibility Trial
Primary Purpose
Periodontitis, Periodontal Diseases, Periodontal Inflammation
Status
Not yet recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Vitamin D supplementation (30 µg/d)
Sponsored by
About this trial
This is an interventional supportive care trial for Periodontitis focused on measuring Vitamin D, 25(OH)D, Cholecalciferol, Periodontitis
Eligibility Criteria
Inclusion Criteria:
- Patients diagnosed with chronic periodontitis according to the 2017 case definition
- Adults, age group 20-60 years
- Periodontitis Stage I-IV (2017 definition)
Exclusion Criteria:
- Systemic illnesses (diabetes, osteoporosis)
- Smoking
- Immuno-suppressive treatment
- Pregnancy
- Daily vit-D supplements
- Solarium
- NSPT within 6 months
- Local anti-microbial treatment
- No natural teeth/peri implantitis
Sites / Locations
- Public Dental Service Competence Centre of Northern Norway
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vitamin D3 (30 µg/d)
Placebo
Arm Description
Subjects will take 30 µg vitamin D3 per day
Subjects will take placebo
Outcomes
Primary Outcome Measures
Change in periodontitis status after treatment (2017 case definition)
Change in periodontitis status after treatment (2017 case definition)
Change in periodontitis status after treatment (2017 case definition)
Change in periodontitis status after treatment (2017 case definition)
Change in periodontitis status after treatment (2017 case definition)
Change in periodontitis status after treatment (2017 case definition)
Secondary Outcome Measures
Change in 25(OH)D after intervention
Change in 25(OH)D after intervention
Change in 25(OH)D after intervention
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention
Change in anti-microbial peptides (LL-37, hBD-2) after intervention
Change in anti-microbial peptides (LL-37, hBD-2) after intervention
Change in anti-microbial peptides (LL-37, hBD-2) after intervention
Full Information
NCT ID
NCT05398770
First Posted
May 25, 2022
Last Updated
May 25, 2022
Sponsor
University of Tromso
Collaborators
Public Dental Service Competence Center of Northern Norway
1. Study Identification
Unique Protocol Identification Number
NCT05398770
Brief Title
Randomized Clinical Trial (RCT) on the Effect of Vitamin D Supplement Prior to Non-surgical Periodontal Therapy: a Feasibility Trial
Official Title
Randomized Clinical Trial (RCT) on the Effect of Vitamin D Supplement Prior to Non-surgical Periodontal Therapy: a Feasibility Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2022 (Anticipated)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Tromso
Collaborators
Public Dental Service Competence Center of Northern Norway
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to test the feasibility i. e. to examine all aspects necessary for the implementation of a future randomized clinical trial that aims to determine whether non-surgical periodontal treatment can be improved by concomitant intake of vitamin D.
Detailed Description
Vitamin D is believed to have anti-inflammatory and anti-bacterial properties. This is hypnotized to play a role in periodontitis. Well-designed RCTs on this theme are lacking. We therefore aim at testing a proposed study design in a pilot study, on vitamin D supplementation and its possible adjunctive effect on non-surgical periodontitis treatment (NSPT).
Altogether 28 patients with a referral for treatment at the Public Dental Service Competence Center of Northern Norway (TkNN), diagnosed with periodontitis Stage I-IV, and within the ages of 20-60 years will be recruited. Participation is voluntary and based on written informed consent.
The participants will randomly be allocated into two groups of equal sizes. The intervention group will receive vitamin D supplementation of 30 µg/day, and the control group will receive placebo tablets. The study is double-blinded.
The participants will be instructed to take the tablets once a day for four weeks prior to the onset of the NSPT, and for two additional weeks after their first NSPT, altogether six weeks. The aim is to ensure that the vitamin D status among those who receive vitamin D supplementation is satisfactory at the start of NSPT and throughout the NSPT period.
At baseline and before the start of intervention a dentist will perform a periodontal examination, including bleeding on probing (BoP), probing pocket depth (PPD), determine lost teeth, mobility, furcation involvement and radiographic bone loss. Clinical measurements in addition to data on age and sex will be obtained from the clinics (TkNN) own medical record system. The participants will also be asked to fill out a digital questionnaire about weight and height, oral hygiene, oral health, and general health. The questions in the questionnaire will be repeated at the end of follow-up, in addition to questions on the whether or not the participants have taken the tablets as prescribed, their experienced in doing so, and finally on behaviors that affect vitamin D status (taken other supplements / use of solarium / sun holidays).
At baseline, at week five and at the end of the study period, gingival crevicular fluid (GCF) and blood samples from blood vessels in the arm will be sampled and analyzed for their content of vitamin D, inflammatory markers and enzymes. As a secondary outcome we also aim to assess the correlations between levels of inflammatory markers in blood and the GCF.
The duration of follow-up depends on how many treatments the dentist considers the patient will need. This is part of the ordinary treatment regimen offered to this patient group. The treatment will take place over a time-period of one month. The patient is then invited to return for a check-up after 6-8 weeks. The total estimated time that each individual will be involved in the study is approximately 11-13 weeks.
Once the pilot study is completed, all steps (both scientific and practical) of the trial will be evaluated in details to assess what worked / did not work / could have worked better - including recruitment, randomization, follow-up, dropout, reason for dropout, patient compliance, side effects, GCF and blood samples; including sampling storage, shipping, analysis and more.
The benefits of running a feasibility trial is that it provides valuable insight and knowledge useful for designing and conducting a future high quality clinical trial on this topic. If vitamin D is confirmed to improve the effect of NSPT in a future clinical trial, improving vitamin D status in patients would be an easy to carry out means in the fight against this disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontitis, Periodontal Diseases, Periodontal Inflammation, Inflammation, Inflammation Gum, Vitamin D
Keywords
Vitamin D, 25(OH)D, Cholecalciferol, Periodontitis
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
28 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D3 (30 µg/d)
Arm Type
Experimental
Arm Description
Subjects will take 30 µg vitamin D3 per day
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will take placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D supplementation (30 µg/d)
Intervention Description
The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
Primary Outcome Measure Information:
Title
Change in periodontitis status after treatment (2017 case definition)
Time Frame
Changes from baseline in bleeding on probing (BOP) at week 5
Title
Change in periodontitis status after treatment (2017 case definition)
Time Frame
Changes in bleeding on probing (BOP) from week 5 to week 11-13
Title
Change in periodontitis status after treatment (2017 case definition)
Time Frame
Changes from baseline in bleeding on probing (BOP) at week 11-13
Title
Change in periodontitis status after treatment (2017 case definition)
Time Frame
Changes from baseline in probing pocket depths (PPD) at week 5
Title
Change in periodontitis status after treatment (2017 case definition)
Time Frame
Changes in probing pocket depths (PPD) from week 5 to week 11-13
Title
Change in periodontitis status after treatment (2017 case definition)
Time Frame
Changes from baseline in probing pocket depths (PPD) at week 11-13
Secondary Outcome Measure Information:
Title
Change in 25(OH)D after intervention
Time Frame
Changes from baseline in plasma concentration of 25(OH)D at week 5
Title
Change in 25(OH)D after intervention
Time Frame
Changes in plasma concentration of 25(OH)D from week 5 to week 11-13
Title
Change in 25(OH)D after intervention
Time Frame
Changes from baseline in plasma concentration of 25(OH)D at week 11-13
Title
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention
Time Frame
Changes from baseline in plasma and gingival crevicular fluid concentration of biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) at week 5
Title
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention
Time Frame
Changes in plasma- and gingival crevicular fluid concentration of biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) from week 5 to week 11-13
Title
Change in biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) over time as response to the intervention
Time Frame
Changes from baseline in plasma- and gingival crevicular fluid concentration of biomarkers (IL-1β, IL-6, IL-8, IL-12, TNFα, CRP, MCP-1, MMP) at week 11-13
Title
Change in anti-microbial peptides (LL-37, hBD-2) after intervention
Time Frame
Changes from baseline in the gingival crevicular fluid concentration of anti-microbial peptides (LL-37 and hBD-2) at week 5
Title
Change in anti-microbial peptides (LL-37, hBD-2) after intervention
Time Frame
Changes in the gingival crevicular fluid concentration of anti-microbial peptides (LL-37 and hBD-2) from week 5 to week 11-13
Title
Change in anti-microbial peptides (LL-37, hBD-2) after intervention
Time Frame
Changes from baseline in the gingival crevicular fluid concentration of anti-microbial peptides (LL-37 and hBD-2) at week 11-13
Other Pre-specified Outcome Measures:
Title
Correlations with biomarkers in blood compared to levels in gingival crevicular fluid
Time Frame
Correlation between biomarkers in blood and gingival crevicular fluid at baseline
Title
Correlations with biomarkers in blood compared to levels in gingival crevicular fluid
Time Frame
Correlation between biomarkers in blood and gingival crevicular fluid at week 5
Title
Correlations with biomarkers in blood compared to levels in gingival crevicular fluid
Time Frame
Correlation between biomarkers in blood and gingival crevicular fluid at week 11-13
Title
Change in self-reported oral health before and after treatment
Time Frame
Changes from baseline in self-reported oral health at end of follow-up (week 11-13)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients diagnosed with chronic periodontitis according to the 2017 case definition
Adults, age group 20-60 years
Periodontitis Stage I-IV (2017 definition)
Exclusion Criteria:
Systemic illnesses (diabetes, osteoporosis)
Smoking
Immuno-suppressive treatment
Pregnancy
Daily vit-D supplements
Solarium
NSPT within 6 months
Local anti-microbial treatment
No natural teeth/peri implantitis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Magritt Brustad, Dr. Scient
Phone
+47 77 64 48 43
Email
magritt.brustad@uit.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Magritt Brustad, Dr. Scient
Organizational Affiliation
Department of Community Medicine, University of Tromso
Official's Role
Principal Investigator
Facility Information:
Facility Name
Public Dental Service Competence Centre of Northern Norway
City
Tromsø
State/Province
Postboks 2406
ZIP/Postal Code
9271
Country
Norway
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gro Eirin Holde, CandOdontPhD
Phone
+47 960 92 090
Email
gro.eirin.holde@tffk.no
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Randomized Clinical Trial (RCT) on the Effect of Vitamin D Supplement Prior to Non-surgical Periodontal Therapy: a Feasibility Trial
We'll reach out to this number within 24 hrs